Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2004-07-07
2010-06-29
Noakes, Suzanne M. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S350000, C514S012200, C514S015800
Reexamination Certificate
active
07745578
ABSTRACT:
This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to promote migratory cell movement away from specific sites in a subject. Specific sites include sites of inflammation, infection, an autoimmune reaction, a tumor and a transplanted organ or tissue.
REFERENCES:
patent: 5750119 (1998-05-01), Srivastava
patent: 2003/0104622 (2003-06-01), Robbins et al.
patent: WO 01/017554 (2001-03-01), None
patent: WO 01/52791 (2001-07-01), None
Wells et al., Biochemistry, vol. 29, 1990, pp. 8509-8517.
Seffernick et al., J. of Bacteriology, Apr. 2001, pp. 2405-2410.
Sequence alignment of instant SEQ ID No. 3 and GenBank X15183 (human HSP90) (Apr. 30, 2009).
Yagita et al. “Molecular Cloning of a Novel Member of the HSP110 Family of Genes, Ischemia-Responsive Protein 94 kDa (irp94), Expressed in Rat Brain After Transient Forebrain Ischemia” J. of Neurochem. 72: 1544-1551 (1999).
Poznansky et al. “Thymocyte emigration is mediated by active movement away from stroma-derived factors” J. of Clin. Invest. 109(8): 1101-1110 (2002).
Shinomiya et al. “Complete Primary Structure and Phosphorylation Site of the 65-kDa Macrophage Protein Phosphorylated by Stimulation with Bacterial Lipopolysaccharide” J. of Immunol. 154: 3471-3478 (1995).
Shrikant et al. “Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness” J. of Immonul. 162: 2858-2866 (1999).
Doughty Dahlia
Poznansky Mark C.
Edwards Angell Palmer & & Dodge LLP
Lauro, Esq. Peter C.
Noakes Suzanne M.
The General Hospital Corporation
LandOfFree
Fugetactic proteins, compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fugetactic proteins, compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fugetactic proteins, compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154882